Virtual Library

Start Your Search

Ronald Damhuis



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries (ID 445)

      12:30 - 13:00  |  Presenting Author(s): Ronald Damhuis

      • Abstract
      • Slides

      Background

      Stereotactic body radiation therapy (SBRT) has become increasingly accepted as a treatment for patients with inoperable early stage lung cancer. We studied the patterns of treatment utilization for stage I non-small cell lung cancer (NSCLC) in three European countries in patients diagnosed in 2015-2016.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      Information from population-based registries in England, Norway and the Netherlands were retrieved, and treatment patterns and two-year survival for patients with clinical stage I were analysed.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      Resection rates were higher in Norway (55%) and England (53%) than in the Netherlands (47%). SBRT use was highest in the Netherlands (41%), followed by Norway (29%) and England (12%). Failure to perform curative intent treatment was more common in England (26%) than either Norway (13%) or the Netherlands (9%). In patients treated with SBRT, pathology confirmation of diagnosis was more common in Norway (70-73%) than in England (44-51%) or the Netherlands (47-50%). Two-year survival rates were better for surgery than for SBRT or conventional radiotherapy and treatment-specific survival was higher in Norway than in the other two countries.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      For clinical stage I NSCLC, SBRT has largely replaced conventional radiotherapy in both Norway and the Netherlands, while just 67% of radiotherapy patients in England receive SBRT. The proportion of patients not receiving any curative treatment was higher in England, especially in the elderly.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      S. Senan: Research grants: Varian Medical Systems, ViewRayInc; Membership of advisory boards: AstraZeneca, MSD. All other authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.